Long Term Chamomile Therapy for Anxiety

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prior research has shown that chamomile may be an effective, short-term anti-anxiety treatment. This study will examine the initial and long-term benefits of chamomile extract therapy for the prevention of recurrent anxiety disorder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of CBD in the Treatment of Anxiety

NCT06672666

Anxiety Generalized Anxiety Disorder Sleep Problems

RECRUITING PHASE2

Enhancement of Calmness and Mood Following Acute Lemon Balm Supplementation During Cognitive Demand in Adults

NCT06183372

Stress Mood Disturbance

COMPLETED NA

Relationship Between Treatment With Bach´s Flower Remedy and Spiritual Well-Being of People With Common Mental Disorder

NCT01324674

Mental Disorders Personal Well Being

COMPLETED PHASE2

TCM Daoyin for Anxiety/Depression: Psychological Effects and Biological Mechanisms

NCT06921512

Anxiety Symptom Depression Symptom

RECRUITING NA

Stress-induced Sleep Deficits and a Complementary Therapy

NCT05280561

Insomnia Due to Anxiety and Fear

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Anxiety disorders are among the most common psychiatric conditions. They affect up to 25% of the US adult population. Generalized anxiety disorder (GAD) is a chronic, recurrent form of the disorder. Although benzodiazepines and serotonin reuptake inhibitors have become the mainstay therapy of GAD, these drugs are often associated with unwanted side effects, habituation, and withdrawal symptoms. Many individuals decline using conventional drug therapy for financial, cultural, or personal reasons such as the stigma of mental illness. As a result, many individuals will seek alternative therapy for their anxiety symptoms. The identification of effective alternative therapies for GAD would be of particular relevance. Among alternative therapies for anxiety, chamomile has been used as a traditional herbal medicine for its calming effect. It is well tolerated and demonstrates pharmacological activity in animal models of anxiety. Despite its widespread use and availability, there has been only one clinical trial of chamomile safety and efficacy in GAD. The current application seeks to build upon the results of that prior chamomile study. In that 8-week, double-blind, placebo-controlled trial, we found a significant superiority of chamomile (vs. placebo) in reducing GAD symptoms. We also found chamomile to be exceedingly well tolerated (vs. placebo). The current application seeks to extend these promising preliminary results by conducting a randomized, double-blind, parallel group, placebo-substitution, long-term safety and efficacy study of chamomile in preventing GAD relapse. For specific aim #1 we will ask: "Does long-term chamomile therapy (vs. placebo) prolong the time to relapse of anxiety symptoms following recovery from GAD?" To answer this question, 180 patients with moderate to severe GAD will receive open-label chamomile extract 500-1,500 mg daily for 8 weeks. Responders to chamomile, who remain well for 4 additional weeks of consolidation therapy, will be randomized to double-blind continuation therapy with chamomile 500-1,500 mg daily or placebo for an additional 26 weeks. We hypothesize that continuation chamomile therapy will result in a prolonged time to relapse (vs. placebo). For specific aim #2 we will ask: "What is the relative safety and tolerability of long-term chamomile therapy (vs. placebo) in patients who have recovered from GAD?" To answer this question, we will examine the following outcome measures: (i) the proportion of patients in each treatment condition who relapse; (ii) the frequency, severity, and duration of treatment-emergent adverse events; (iii) the frequency of discontinuation symptoms during initial double-blind therapy; and, (iv) the frequency of early study discontinuation. We hypothesize that chamomile therapy will result in a lower proportion of anxiety relapses and a lower study discontinuation rate (vs. placebo). We further hypothesize that chamomile therapy will result in a similar frequency of discontinuation symptoms and treatment-emergent adverse events (vs. placebo).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Generalized Anxiety Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chamomile Extract

Pharmaceutical grade oral chamomile extract.

Group Type EXPERIMENTAL

Chamomile (Matricaria recutita)

Intervention Type DRUG

500 mg 3 times daily

Placebo

Pharmaceutical grade lactose monohydrate.

Group Type PLACEBO_COMPARATOR

Chamomile (Matricaria recutita)

Intervention Type DRUG

500 mg 3 times daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chamomile (Matricaria recutita)

500 mg 3 times daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Chamomile

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women at least 18 years old (all races and ethnicity)
* DSM IV diagnosis of GAD as the primary anxiety disorder
* Baseline GAD-7 score ≥ 10
* Baseline CGI/S score at least 4
* Not taking anti-anxiety medication (e.g., Benzodiazepines, buspirone, antidepressants)
* Not taking antidepressant, mood stabilizer, or tranquilizer therapy for a prior DSM IV Axis I mood disorder that is in remission
* Able to understand and provide informed consent
* Able to participate in a 38-week study

Exclusion Criteria

* Patients \< 18 years old
* Primary DSM IV Axis I anxiety disorder other than GAD (e.g., panic disorder with or without agoraphobia, phobia disorder, acute stress disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance-induced anxiety disorder)
* Current DSM IV Axis I psychotic disorder
* Substance abuse or dependence within the prior 3 months
* Current DSM IV Axis I bipolar or major depressive disorder \[Note: Patients with co-morbid depressive disorder NOS (e.g., minor depression, recurrent brief depressive disorder, or premenstrual dysphoric disorder (PMDD)\] will not be excluded
* Unstable medical condition
* Allergy to chamomile
* Documented allergy to plants of the asteraceae family (e.g., ragweed, asters, chrysanthemum)
* Allergic to mugwort or birch pollen
* Concurrent anti-anxiety tranquilizer, antidepressant or mood stabilizer therapy
* Concurrent use of over-the-counter anti-anxiety and/or antidepressant preparations (e.g., chamomile, St. John's Wort, kava kava)
* Concurrent use of established antidepressant, mood stabilizer, or tranquilizer therapy for pre-existing affective disorder. \[Note: Patients with a history of affective disorder (in remission) who are not currently taking antidepressant, mood stabilizer, or tranquilizer therapy are not excluded from the trial\]
* Women of child-bearing potential not willing to use a medically proven form of contraception
* Positive pregnancy test
* Actively suicidal or suicide attempt within the preceding 12 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No